StockDrifts LogoStockDrifts

ImmuneOncia 424870

Company
이뮨온시아ImmuneOncia
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-05-22

ImmuneOncia (424870) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for ImmuneOncia is dated 2025-05-19; the most recent is 2026-05-22. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-07-22BUY주식매수청구권 행사
PAIK SOONMYUNG
Outside Director65.2K₩2,760-2.2%₩180M ($125K)
2026-05-22SELL기타
유한양행
Yuhan Corporation
--2.7M₩5,800-14.1%₩15.9B ($11.0M)
2026-05-22BUY기타
유한양행
Yuhan Corporation
-345.5K₩5,800+14.1%₩2.0B ($1.4M)
2026-05-22BUY유상신주취득
유한양행
Yuhan Corporation
-2.7M₩5,800+14.1%₩15.9B ($11.0M)
2026-05-21BUY유상신주취득
PAIK SOONMYUNG
Outside Director8.5K₩5,310+24.7%₩45M ($32K)
2026-04-23SELL장외매도
유한양행
Yuhan Corporation
--8.7M₩7,200+2.9%₩62.4B ($43.3M)
2026-04-17BUY기타
유한양행
Yuhan Corporation
-11.1M₩7,680-5.1%₩85.0B ($59.0M)
2026-02-06BUY주식매수청구권 행사
PAIK SOONMYUNG
Outside Director33.0K₩9,700+0.6%₩320M ($222K)
2025-05-19BUY신규상장
유한양행
Yuhan Corporation
-48.9M₩7,500+30.1%₩366.7B ($254.6M)

Frequently asked questions

Who has been buying ImmuneOncia stock?
0 distinct insiders have filed 0 disclosed insider purchases in ImmuneOncia (424870), most recently on 2026-05-22. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does ImmuneOncia have?
ImmuneOncia has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-05-19 to 2026-05-22.
Where does StockDrifts get ImmuneOncia insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for ImmuneOncia. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.